Konica Minolta’s Acquisition of Ambry Genetics at US$1 Bn


Published Date : Jul 07, 2017

Konica Minolta, Inc. a Japanese company specializing in imaging technologies, announced on July 5, 2017 that it has agreed to make an acquisition of Ambry Genetics, a privately held U.S.-based company pioneering in genetic testing solutions, for a valuation of US$1 billion. The company believes this to be a significant strategic step, the first in a series, in consolidating its presence in the healthcare diagnostics market. The shift will help it become a leader in the area of precision medicines. After the deal is finalized, expectedly by October 2017, Ambry would retain its name and will become a consolidated subsidiary of the Japanese company.

High-Sensitivity Tissue Testing (HSTT) at the Forefront

The high-sensitivity tissue testing (HSTT), an advanced immune-staining technology, launched by Konica Minolta in 2015, will be integrated with the genetics-based screening techniques offered by Ambry. By leveraging the potential of genetic testing solutions, the Japanese player opines that the acquisition will broaden its spectrum of diagnostic solutions aimed for numerous pharmaceutical players, healthcare providers and payers, and end consumers.

The HSTT employs fluorescent nanoparticle technology to identify disease causing proteins with enhanced accuracy and precision, in the earliest stage. The company first used the solution in oncology and facilitated clinicians in making informed decision on the diagnosis and treatment of diseases. Using Ambry’s advanced genetic screening technologies, the company hopes to develop solutions to help clinicians in diagnosing and treating hereditary cancer.

Marrying Of Technologies to Open Up New Avenues in Drug Discovery

Ambry, since it offered panels for hereditary cancer patients and clinical next-generation sequencing, has performed over one million genetic tests across various medical specialties.

Konica Minolta revealed that the capabilities of the combined technologies will be first launched in Japan followed by European countries. The recent strategic shift will enable the company to develop advanced proteomic solutions and bio-imaging that will benefit patients, physicians, and pharmaceutical players, echoes Kiyotaka Fujii, Senior Executive Officer of Konica Minolta. This will open up exciting opportunities in drug discovery.

Konica Minolta Healthcare Americas (MHUS), a wholly-owned subsidiary of the company, will collaborate with Innovation Network Corporation of Japan (INCJ) to offer US$800 mn to the U.S.-based player at the time the deal is finalized.